Company Filing History:
Years Active: 2011-2015
Title: Frida Ekholm Pettersson: Innovator in Neurodegenerative Disease Research
Introduction
Frida Ekholm Pettersson is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of neurodegenerative diseases, particularly Alzheimer's disease. With a total of two patents to her name, her work focuses on innovative therapeutic approaches that target specific proteins associated with these conditions.
Latest Patents
Frida's latest patents include "Protofibril selective antibodies and the use thereof." This invention relates to an isolated antibody, or fragment thereof, that exhibits high affinity for human Aβ protofibrils. The invention encompasses compositions that include the antibody and a pharmaceutically acceptable buffer. Additionally, it outlines a method for preventing or treating Alzheimer's disease by administering the antibody or a related composition to patients. Another patent under her name also pertains to the prevention, treatment, and diagnosis of neurodegenerative diseases, specifically targeting high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation. These antibodies are designed to effectively clear Aβ protofibrils while minimizing inflammation.
Career Highlights
Frida has worked with notable companies in the field, including Bioarctic Neuroscience AB. Her research and innovations have positioned her as a key figure in the development of therapies aimed at combating Alzheimer's disease and similar neurodegenerative disorders.
Collaborations
Throughout her career, Frida has collaborated with esteemed colleagues such as Pär Gellerfors and Lars Lannfelt. These partnerships have further enhanced her research and contributed to the advancement of her innovative projects.
Conclusion
Frida Ekholm Pettersson is a trailblazer in the realm of neurodegenerative disease research, with her patents reflecting her commitment to finding effective treatments for Alzheimer's disease. Her work continues to inspire advancements in medical science and offers hope for patients affected by these challenging conditions.